Given that IL-6 blockade reduces bone resorption in inflammatory diseases, asiatic acid may represent a natural, multi-target adjunct candidate for inflammation-driven osteoporosis, particularly in postmenopausal or chronic inflammatory settings [53]. Here, IL6 is linked to osteoporosis.